Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04645953 · ClinicalTrials.gov registry record · Phase 2
Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome
A Phase 2 study, sponsored by Alexza Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT04645953 is a Phase 2 study that has completed, run by Alexza Pharmaceuticals. The registered enrollment target is 150 participants.
The verdict
NCT04645953, a Phase 2 study, has completed, sponsored by Alexza Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, parallel group, placebo-controlled, efficacy and safety study of adult outpatients diagnosed with CVS and experiencing recurring episodes of stereotypical vomiting.
Interventions
- COMBINATION_PRODUCT 3mg AZ-010
- COMBINATION_PRODUCT 1mg AZ010
- COMBINATION_PRODUCT Staccato Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2021-02-05 |
| Est. Completion | 2022-07-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04645953
The ClinicalTrials.gov registry entry for NCT04645953 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexza Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 3mg AZ-010 is the first listed.
NCT04645953 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04645953 about?
NCT04645953 is a clinical study titled "Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome". This is a multicenter, randomized, double-blind, parallel group, placebo-controlled, efficacy and safety study of adult outpatients diagnosed with CVS and experiencing recurring episodes of stereotypical vomiting.
What is the current status of trial NCT04645953?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2021-02-05. Estimated completion is 2022-07-26.
What interventions are being tested in trial NCT04645953?
The interventions under investigation include: 3mg AZ-010 (COMBINATION_PRODUCT), 1mg AZ010 (COMBINATION_PRODUCT), Staccato Placebo (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04645953?
This trial is sponsored by Alexza Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.